Navigation Links
China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Company's Convertible Notes in August 2008
Date:10/25/2011

BEIJING, Oct. 25, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has recently received approximately 2,200,000 of its American Depositary Shares ("ADSs") from two investment banks which borrowed the ADSs in connection with the issuance of the Company's convertible notes in August 2008. The ADSs will no longer be available for lending again.  There are still approximately 2,010,000 of the Company's ADSs which are held by the banks and are available for investors which are hedging their investment in the Company's convertible notes. Except for the above lending arrangement, the Company does not engage in any lending of its ADSs.

In addition, Chengxuan International Limited, the largest shareholder of the Company, has confirmed to the Company that it currently does not, and has no intention to, lend any of its shares in the Company to third parties.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

Contact

Winnie Yam
Tel: 852-2511-9808
Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a ... (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister ... published by MarketsandMarkets, The market is projected to reach USD 52.37 Billion ... 6.5% during the forecast period. Continue Reading ... ...
(Date:2/20/2017)... VALLEY COTTAGE, New York , February 20, 2017 ... instruments a regularized absorption of calcium and phosphorous minerals ... pivotal role of vitamin D ingredients in maintaining a ... beverages or medicines containing vitamin D ingredients is growing ... attested the advantage of consuming vitamin D ingredients for ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 19, 2017 /PRNewswire/ ... its revenue cycle portfolio and thought leadership at ... be receiving a category leader award from KLAS. ... Learn panel discussion focused on how market trends ... future -  particularly a sophisticated, comprehensive Patient Access ...
Breaking Medicine Technology:
(Date:2/20/2017)... St. Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... of its research and education building. A topping out ceremony on Friday marked the ... , The building, set to open in Fall 2018, will serve as a center ...
(Date:2/20/2017)... ... 20, 2017 , ... Florida Hospital Pepin Heart Institute has ... machine, a state-of-the-art device that breaks up life-threatening blood clots by combining clot-dissolving ... , “We greatly appreciate this gift from Constellation Brands. We are also grateful ...
(Date:2/19/2017)... ... ... Glitch is a set of 30 glitch distortion logo reveals made exclusively for Final ... a glitch reveal in just a few clicks of a mouse. Customizable glitch style effects ... Use these presets to add a uniquely animated logo to any photos or videos. Its ...
(Date:2/18/2017)... (PRWEB) , ... February 17, ... ... Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, ... Are manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced ...
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
Breaking Medicine News(10 mins):